Pfizer (PFE) stock vs the S&P 500 and pharmaceutical stocks
As of 20 November 2026, Pfizer (PFE) is beating both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.
Where Pfizer stands now
As of 20 November 2026, Pfizer is ahead of the S&P 500 on every window Zensei tracks, from one month to one year. The trend against the market is intact on all horizons.
Inside its group, PFE is slipping: still ahead of pharmaceutical stocks (PPH) over three months, but behind over the past month. As a group, pharmaceutical stocks are gaining ground on the S&P 500 right now. The group is in transition, so the stock's place inside it matters more than usual.
Pfizer is 5.1% of PPH, so its moves weigh on the fund. It sits in 3 of the sector and theme funds Zensei tracks. The thing to watch is the gap to its group: as long as it stays ahead of both the market and its peers, the trend is intact.
PFE vs the S&P 500: returns
Pfizer and the S&P 500 (SPY) side by side, over each window Zensei tracks.
Prices as of · computed from daily adjusted closes · how we measure
PFE against pharmaceutical stocks, in depth
See the size of the gap between Pfizer and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.
See the full analysisWhich ETFs hold Pfizer?
3 funds that Zensei tracks hold PFE, by weight. The fund with the largest weight is its sector on this page.
Pfizer competitors
The largest other holdings of VanEck Pharmaceutical ETF (PPH), with their return over the past month.
Pfizer stock: common questions
Is Pfizer stock beating the S&P 500?
As of 20 November 2026, Pfizer (PFE) is down 7.7% over the past month. The S&P 500 is down 10.3% over the same month. Over three months, the stock is down 1.0% and the S&P 500 is down 9.7%.
Which ETFs hold Pfizer?
As of 20 November 2026, 3 funds that Zensei tracks hold PFE. Its largest weight is in VanEck Pharmaceutical ETF (PPH), at 5.1%. It is also in Health Care Select Sector SPDR (XLV, 2.6%), SPDR S&P 1500 Momentum Tilt ETF (MMTM, 0.4%).
Who are Pfizer's competitors?
As of 20 November 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) are Eli Lilly (LLY), Merck & Co Inc (MRK), Novo Nordisk (NVO), Mckesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Pfizer sits next to among pharmaceutical stocks.
Is Pfizer doing better than other pharmaceutical stocks?
As of 20 November 2026, Pfizer (PFE) is ahead of pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.
Recent changes
- ·Beating the market, trailing pharmaceutical stocks → beating the market and pharmaceutical stocks
- ·Beating the market and pharmaceutical stocks → beating the market, trailing pharmaceutical stocks
- ·Among the strongest → beating the market and pharmaceutical stocks
- ·Beating the market and pharmaceutical stocks → among the strongest
- ·Among the strongest → beating the market and pharmaceutical stocks
Track Pfizer against pharmaceutical stocks and the market
Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.